BioCancell Announces Successful Results In Pancreatic Cancer Treatment Trial

Israeli biomedical company BioCell, which develops treatments for cancer, reports positive preliminary findings in trials conducted with BC-819. The drug, developed for treatment of pancreatic cancer, has registered a 66 percent success rate in stopping the diseases progress and even reducing tumor size. The trial’s final results will be published in the beginning of 2013.